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Abstract
Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disorder that mostly affects the synovial joints and can
promote both cartilage and bone tissue destruction. Several conservative treatments are available to relieve pain and control the
inflammation; however, traditional drugs administration are not fully effective and present severe undesired side effects.
Hydrogels are a very attractive platform as a drug delivery system to guarantee these handicaps are reduced, and the therapeutic
effect from the drugs is maximized. Furthermore, hydrogels can mimic the physiological microenvironment and have the
mechanical behavior needed for use as cartilage in vitro model. The testing of these advanced delivery systems is still bound to
animal disease models that have shown low predictability. Alternatively, hydrogel-based human dynamic in vitro systems can be
used to model diseases, bypassing some of the animal testing problems. RA dynamic disease models are still in an embryonary
stage since advances regarding healthy and inflamed cartilage models are currently giving the first steps regarding complexity
increase. Herein, recent studies using hydrogels in the treatment of RA, featuring different hydrogel formulations are discussed.
Besides, their use as artificial extracellular matrices in dynamic in vitro articular cartilage is also reviewed.
Graphical Abstract
1 Introduction
Hydrogels are three-dimensional (3D) networks of hydro-
philic polymers able to absorb vast amounts of biological
fluids or water [1, 2]. Hydrogels are formed by physical and
chemical crosslinking. Physically crosslinked hydrogels are
produced through molecular entanglements, ionic, hydro-
gen bonding, or hydrophobic forces. These hydrogels are
structurally weak, and their gelation is reversible. Chemical
hydrogels are covalently crosslinked by redox reactions,
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photo-polymerization, Michael reactions, enzymatic reac-
tions, or disulfide-forming reactions, which are strong and
irreversible bonds [3, 4]. Hydrogels, according to the
source, can be classified into the natural and the synthetic
group [5]. Natural and synthetic polymers present advan-
tages and disadvantages, to increase the physicochemical
and biological properties, several materials can be used
together [6].
Experiments with 2D cell cultures are the usual practice
in cell-based assays for various biomedical research pur-
poses, presenting, however several limitations. This cell
culture system is incapable of reproducing the anatomical
and biochemical properties of tissues and organs [7].
Therefore, the development of model systems that better
mimic the physiological microenvironment of the tissue and
disease, such as stiffness, topography, and biochemistry,
with the capacity to execute prolonged culture tests while
maintaining tissue function is required [8]. In vivo, cells are
embedded by extracellular matrix (ECM) that plays an
important role in several cellular processes such as reg-
ulating growth and cell–cell communication and assembling
cells into various tissues and organs. So, developing an
in vitro cell culture environment that mimics the native
ECM is required [9]. Hydrogels are one of the leading
biomaterials used and appropriate options due to their
unique properties, high water content, porosity, and flex-
ibility, they can mimic the native ECM. Additionally,
hydrogels do not affect the metabolic processes of living
organisms, and metabolites can pass easily through the
hydrogels [10]. So, such an engineered native-like ECM is
most likely to offer cells with rational indications for
diagnostic and therapeutic investigations. Due to these
appealing features, an extensive range of 3D hydrogel
platforms have been developed to mimic better the natural
tissue environment in vitro [11]. Traditional approaches
include cellular encapsulation into hydrogels, cell seeding
on porous, and fibrous hydrogels. However, advanced
hydrogel platforms have emerged to use hydrogels in
functional tissue models, including hydrogel microspheres,
hydrogel sandwich systems, hydrogel-based microwells,
and 3D bioprinted tissue–hydrogel. Furthermore, hydrogels
are usually incorporated within culture platforms such as
transwell microfluidic devices (Fig. 1) [12]. Hydrogels have
been used to develop a wide range of tissue and disease
models. These 3D networks of hydrophilic polymers can
undergo physiological swelling and have the mechanical
behavior desired for use as an articular in vitro model [13].
The unique physical properties of hydrogels (high por-
osity, controlled drug release, biocompatibility, biode-
gradation, and flexibility) make this system an appealing
platform for drug delivery applications [2]. The porosity of
hydrogels allows the encapsulation of drugs into the gel and
consequent drug release at a rate dependent on the diffusion
coefficient of the molecule by the hydrogel network [14].
The hydrogels can be produced in a way in which drugs are
released slowly, keeping a high local concentration of the
drug in the place where they are administrated for a long
time [15, 16]. Hydrogels are also biocompatible due to their
high content and structural and mechanical similarity of
hydrogels to the ECM. The biodegradation pattern is an
essential parameter for a drug delivery system. The con-
trolled drug release and degradation profile may be design
into hydrogels via the hydrolytic, environment (pH, tem-
perature), or enzymatic pathways (Fig. 2) [17–20].
The administration of hydrogels is also versatile, for
example, through oral and topical administration, implan-
tation, or it can be injected [21]. The selection of delivery
method is based on the improvement of the overall efficacy
and patient compliance.
Drug release through topical route offers several advan-
tages and novel approach. These potential advantages
include improved patient compliance, ease of application to
Fig. 1 Schematic illustration of
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the skin, and allow to deliver drugs more selectively to a
specific local of action. The main disadvantages arise when
the skin acts as a natural barrier that becomes difficult for
most drugs to penetrate [22]. Besides that, the scaffolds can
be implanted on a site-specific to a more controlled release
of active compounds. This allows to preventing side effects
caused by high doses and frequent administration. How-
ever, implantable hydrogels are a more invasive and painful
method with a higher cost [14, 23]. Injectable hydrogels
demonstrate promising properties as carriers for targeted
drug delivery. They are attracting more attention because
they are more comfortable, less painful, have a faster
recovery period, lower costs, and present fewer complica-
tions and side effects [24].
Rheumatoid Arthritis (RA) is an autoimmune and
chronic inflammatory condition. The cause of RA remains
poorly known but can involve genetic and environmental
factors [25, 26]. The pathology of RA is characterized by
infiltration of several inflammatory cells into the synovial
membrane and by subsequent cartilage and bone tissue
destruction [27, 28]. The pathogenesis begins with the
activation of immune cells that promotes the production of
pro-inflammatory cytokines which support cell–cell com-
munication in immune response and stimulate the move-
ment of inflammatory cells toward to synovial membrane
[29]. The inflammation of the synovium invades adjacent
cartilage promoting articular destruction. The articular
damage is featured by a hypoxic environment and angio-
genesis [29]. The clinical manifestations comprise red-
ness, swelling, and limitation the range of motion.
Currently, several treatments are available to relieve pain
and control inflammation. However, traditional drug
administration often involves high dosages or frequent
administration to promote a therapeutic effect, which can
decrease overall efficacy and result in severe side effects
(heart problems, kidney damage, diabetes, lung infections,
among others) [30].
Drug delivery systems are emerging to address existent
failures in traditional systems. The advantages of these new
approaches are the capacity to deliver a drug more selec-
tively to a specific site allowing more accurate and less
frequent dosing. Furthermore, decrease variability in sys-
temic drug concentration, the absorption is more consistent
with the site and action mechanism, and reduces the side
effects of therapeutics.
Hydrogels are a particularly appealing type of drug
delivery system to ensure these disadvantages are mini-
mized and the therapeutic benefits from the drug are opti-
mized [16, 31].
2 Hydrogels for the treatment of RA
Several treatments, including non steroidal inflammatory
drugs (NSAIDs), glucocorticoidds (GCs), disease-
modifying anti-rheumatic drugs (DMARDs) and biologi-
cal agents, are available to relieve pain and control
inflammation with the final goal to achieve disease remis-
sion [32]. NSAIDs such as ibuprofen and indomethacin
have both analgesic and anti-inflammatory properties but
do not change the course of the disease of RA or prevent
joint destruction. Most commonly, NSAIDs are available
as oral form [33]. GCs such as Betamethasone and Dex-
amethasone present anti-inflammatory and immunor-
egulatory activity. They can inhibit neutrophil migration to
sites of inflammation and interfere with cytokine stimula-
tion. GCs can be administered orally, intravenously, or
intra-articular injection [34]. DMARDs such as Penicilla-
mine and Hydroxychloroquine include a large group of
drugs that reduce the progression of joint erosion. Although
both NSAIDs and DMARDs agents improve symptoms of
active RA, only DMARDs agents have shown to alter the
disease course. These therapies can be administrated orally
or subcutaneously [35]. Biological agents such as Eta-
nercept and Infliximab are a class of drugs that act by
decreasing the inflammatory response in affected joints.
Biological agents target specific components of the
immune system that play an important role in the suste-
nance of the disease process and tend to work more quickly
than conventional DMARDs. The most of biological agents
are currently administrated through subcutaneous/intra-
muscular injection [36].
Current strategies for the treatment of RA can decrease
inflammation in the joints, alleviate pain, and slow down
joint damage; however, the treatments are associated with
poor pharmacokinetic distribution to the specific site of
disease, short half-life, and several side effects [37]. The
hydrogels offer suitable drug delivery vehicles to guarantee
that the handicaps of traditional drugs are reduced, and the
therapeutic effects from the medications are maximized.
Fig. 2 Drug delivery hydrogel in response to several physical and
chemical stimuli
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Several studies report the potential application of
hydrogels in the treatment of RA. In this section, the studies
provided were selected among the more promising strate-
gies using hydrogels in the treatment of RA summarized
(Table 1).
The most common techniques are based on the use of
injectable hydrogels to treatment of RA. Qi et al. [38]
developed intra-articular administrated chitosan thermo-
sensitive hydrogels with diclofenac sodium (DS)-loaded
alginate microspheres to assess the potential of hydrogels as
drug delivery systems for promoting the anti-inflammatory
effect. The results showed that the anti-inflammatory effi-
cacy of hydrogels after 3 weeks was higher than that of
diclofenac solution and chitosan hydrogels alone. A study
performed by Cokelaere et al. [39] evaluated the adminis-
tration intra-articular sustained of two formulations of cel-
ecoxib (40 and 120 mg/g) in a poly(ε-caprolactone-co-
lactide) PCLA-PEG-PCLA triblock copolymer in an equine
repeated lipopolysaccharide (LPS) synovitis model. Only
one intra-articular injection of the low dose (LCLB)-gel or
high dose (HCLB)-gel demonstrated a sustained and con-
trolled intra-articular release in healthy and inflamed joints.
The celecoxib formulations presented a soft effect on
inflammatory and synovial fluid biomarkers, but these
returned to the threshold 1 week after administration. High
levels of celecoxib were detected in the joint after 1 month,
but no overall anti-inflammatory effects were observed,
maybe due to the moderate synovitis. Furthermore, there
were no side effects during the study period. Therefore, this
approach should be assessed for its impact on longer-term
relief of inflammatory joint pain. Yeo et al. [40] evaluated
the capability of intra-articular injection of the nitric oxide
(NO)-scavenging nanogel (NO-Scv gel) to treat RA. After
35 days, the NO-Scv gel decreased inflammation levels and
showed good biocompatibility. Moreover, the therapeutic
effect of the NO-Scv gel in diminishing the onset of RA is
observed in a mouse RA model when compared to the
effects of dexamethasone alone (Fig. 3). Wang et al. [41]
produced a sustained release formulation-intra-articular
injectable dexamethasone-encapsulated thermosensitive
hydrogel (DLTH) chitosan–glycerin–borax as the carrier for
the suppression of inflammation and pain in collagen-
induced arthritis (CIA) rats. The data showed that paw
swelling, arthritis scores, and joint inflammation destruction
were reduced in the group treated with DLTH after 3 weeks.
DLTH demonstrated down-regulated serum IL-17A and
mRNA levels of inflammatory factors. Furthermore, DLTH-
treated rats elucidated the pain-reducing effects of DLTH.
So, these results suggested that DLTH joint injection pre-
vents synovial inflammation. A study made by Kuçuk-
turkmen et al. [42] analyzed the effect of in situ gelling
hydrogel formulations (Poloxamer 407 and chitosan) con-
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poly(ε-caprolactone) (PCL) nanoparticles for intra-articular
injection. After 1-month prolonged in vitro release of DS
was reached by using polymeric nanoparticles with in situ
hydrogels.
A study made by Dong et al. [43] produced cationic
agarose injectable hydrogels to deliver antisense oligo-
deoxynucleotides (ASOs) targeting the mRNA of TNF-α.
Different kinds of animal models were used to assesses the
therapeutic benefits of ASO-Gel, including CIA, carrageen/
LPS-induced arthritis, adjuvant-induced arthritis (AA), and
models. After 28 days of treatment, the effects of ASO-c-
agarose in decreasing inflammation and tissue destruction
were demonstrated in most tested animals, with reduction of
main inflammatory cytokines and decrease of joint swelling
and tissue destruction. Another study reported the produc-
tion of an injectable self-assembled nanofibrous hydrogel,
which can encapsulate and release agents in response to
matrix metalloproteinases (MMP-2 and MMP-9) that are
upregulated in RA. The results showed that nanofibrous
gels could persist stably after 8 weeks of injection into
healthy joints of mice, and in vitro studies showed that
release loaded agents in response to synovial fluid from
arthritic patients [44]. Another study investigated the effect
of nanoiguratimod-loaded hyaluronic acid–acrylate hydro-
gel (NanoIGUR-loaded hydrogel) composites in CIA rats to
improve the bioavailability of drug and to alleviate side
effects through the sustained release of therapeutics [45].
The results demonstrated superior bioavailability and longer
half-life time with NanoIGUR-loaded hydrogel than tradi-
tional iguratimod. Animal experiments for 21 days showed
that subcutaneous injection of NanoIGUR-loaded hydrogel
(10 mg/kg every 3 days) and traditional iguratimod (10 mg/
kg daily) exhibited identical efficacy in diminishing arthritis
index score, pathological score, and expression of inflam-
matory cytokines [45]. Joshi et al. [46] reported the pro-
duction of a triglycerol monostearate (TG-18) injectable
hydrogel encapsulated with triamcinolone acetonide (TA)
releases after being in contact with enzymes or synovial
fluid from patients with RA. In arthritic mice, hydrogel
encapsulated with a fluorescent dye showed flare-dependent
Fig. 3 Schematic Illustration of
intra-articular injection of NO-
Scv Gel in suppressing of RA in
a mouse model. Reprinted with
permission from [40]. Copyright
(2019) American Chemical
Society
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disassembly assessed as a loss of fluorescence. Furthermore,
a unique dose of TA-encapsulated hydrogel decreased
arthritis manifestation in the injected paw after 14 days.
Besides injectable hydrogels, the implanted and topical
hydrogels are widely used in the treatment of RA. Liu et al.
[47] developed a fibrin gel- and poly(l-lactide-co-glycolide)-
poly(ethylene glycol)-poly(l-lactide-co-glycolide) hydrogel-
assisted bone marrow mesenchymal stem cells (BMMSCs)
referred to FGB and HGB groups, respectively, to be intra-
articullary transplanted into subchondral defects of
ovalbumin-induced arthritis in rabbits for the treatment of
antigen-induced arthritis. The BMMSCs have an important
role in secreting soluble factors that promote tissue regen-
eration. Furthermore, these cells provide an immunor-
egulatory ability and induce immunosuppressive effects
demonstrated in several autoimmune diseases. The adminis-
tration of BMMSCs reduced inflammatory cytokine levels
and improved joint swelling in both groups, after 12 weeks.
Furthermore, the preservation of adjacent cartilage and
enhanced cartilage repair was detected. The results showed
that HGB group presented a better therapeutic benefit than
the FGB group. Goindi et al. [48] developed microemulsion-
based topical hydrogels of Tenoxicam (TNX) to treat
arthritis. In vivo anti-inflammatory and anti-arthritic activity
of the TNX formulations was assessed using several
inflammatory models. Microemulsion formulations demon-
strated to be better in controlling inflammation than tradi-
tional topical forms and presented efficacy similar to an oral
formulation. A study made by Garg et al. [49] investigated
the use of nanostructured lipid carriers (NLCs) produced
through lipid mixture and chemical permeation increaser-
based hydrogel for an effective transdermal delivery of
methotrexate (MTX) to induce apoptosis of RA. The
immunocytochemistry to detect IL-6 expression and immu-
nofluorescence assay showed that promoted apoptosis
occurred in an in vitro arthritis model treated with NLCs-
MTX. It was verified decreased inflammation and activated
apoptosis promoted by MTX encapsulated NLCs in rheu-
matoid arthritic cells. Furthermore, histopathological analysis
of rat skin suggested the safety potential of NLCs after 24 h.
Posteriorly the same group [50] evaluated the effect of MTX
encapsulated NLCs and chemical enhancer co-incorporated
hydrogel (gel-(MTX-NLCs+CE)) for competent transder-
mal delivery of MTX in a complete Freund’s adjuvants
(CFA)-induced arthritis in rats. The gel-(MTX-NLCs+CE),
gel-MTX, gel-(MTX-NLCs) was applied on paws and ankles
of CFA induced arthritis rat model once a day for 17 weeks.
Results showed that the transcutaneous ability of MTX-
loaded NLCs and CE co-incorporated hydrogel significantly
reduced the inflammation in the RA animal model. Sallam
et al. [51] developed a lecithin organogels transdermal
delivery system for diflunisal and studied human skin pene-
tration capability compared to optimized microemulsion-
based hydrogel. The lipogels delivered a significant amount
of drug through the skin than the hydrogel after 24 h. The
constitution of lecithin showed to affect the skin permeability
increasing the capability of the lipogel. Another study
developed MTX aspasomes encapsulated into a hydrogel and
tested in AIA model in Wistar rats [52]. Transdermal appli-
cation of MTX-loaded aspasome hydrogel in model disease
demonstrated a more significant decrease of rat paw diameter,
tumor necrosis factor-alpha (TNF-α), interleukin (IL-1) β,
cartilage damage, inflammation, pannus formation, and bone
resorption when compared to arthritic control rats after
21 days. Furthermore, the group treated with free MTX
exhibited intermediate effects however, the group treated
with free aspasome did not show to have an effect. The
results demonstrated that drug-loaded therapeutically active
carrier system presented a non-invasive controlled release
transdermal formulation with good drug encapsulation, drug
permeation rate, and showed a more effective therapeutic
effect in treatment of RA than the drug alone [52].
The list of U.S. Food and Drugs Administration approved
drugs for RA is still limited [37, 53], and RA is still an
incurable disease with a high impact on the patient’s life-
style. The drug development process has systemic problems,
several of them related to the use of animal (non-human)
models. This problem, alongside its alternatives, is discussed
in the following section, reviewing the use of hydrogels as
artificial matrices to develop cartilage disease models.
3 Hydrogels as artificial extracellular
matrices for dynamic in vitro models
The process of therapeutic approval is long from in vitro
tests to widespread medical practice. With the increased
costs of drug development, the paradigm of using animal
experimentation as a predictor of results in humans has been
questioned [54, 55]. Animal models are considered the gold
standard in preclinical studies of pathophysiological
mechanisms of RA. They present many similarities with
human arthritic diseases and are widely used for testing new
therapeutic strategies [56, 57]. However, the animal models
present some limitations, such as limited development of
arthritis, pathophysiology in animals does not completely
mimic the human pathogenic disease and, are inadequate for
high drug screening [58].
After revising several systematic reviews evaluating results
from animal experimentation, during the last two decades
several publications have emphasized the shortcomings of
animal testing [54, 59–62]. A group of academia and industry
experts presented recently an alternative for the near future to
animal models: human-based microphysiological models,
developed with the principles of tissue engineering. These
systems have the advantage to have human cells, annulling the
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issue of between species results translation. However, it carries
several engineering challenges, mostly bound to organs’
complexity and systemic dynamics [63].
To produce a fully biomimetic model of a joint’s carti-
lage it is necessary to ensure that these dynamics are
transposed from in vivo to in vitro [64].
A biomimetic dynamic articular cartilage model must
include a biocompatible hydrogel, with physiological values
of physical and biochemical cues for chondrogenesis; multi-
axial mechanical stimulation, mimicking the articulated
limbs; and physiological synovial fluid shear stress, trans-
porting nutrients and regulating the soluble oxygen levels
[65]. To have an improvement on the outcome of drug
development, existing such models, with throughput and
scale-up capacity in a near future, it is necessary that inno-
vative therapeutics systems are developed meanwhile [66].
The near-physiological dynamic systems most com-
monly used are Gel-based systems as artificial extracellular
matrices combined with a dynamic environment, bior-
eactors, or microfluidic devices [67, 68].
Several studies using hydrogels as ECM and bioreactors
for articular cartilage was explored deeper its tissue-
specific particularities. All of the mentioned models are 3D
cultured using biomaterials to support the growth and
physiologic biomechanics of tissue cells. For this purpose,
these biomaterials are processed into biocompatible
hydrogels or scaffolds. Biocompatibility implies bio-
functionality, meaning that these biomaterials not only
must promote cell viability and growth but also promote
tissue-specific phenotype and physiology. Thus, the
selection of the biomaterials used is crucial for the devel-
opment of a representative model.
To improve clinical outcomes and simplify a larger use
of engineered tissues, bioreactor systems able of increasing
and monitoring neotissues is needed. A study made by
Meinert et al. [69] developed an innovative bioreactor
system (Fig. 4i) able to applying specific uni- or biaxial
mechanical stimulation to developing cartilage neotissues in
a fully controlled and automated way to improve the quality
of biological implants and decrease the manufacturing
costs. They investigated the effects of pre-culture and var-
ious uni- and biaxial loading regimes on human chon-
drocyte gene expression in gelatin methacryloyl and
hyaluronic acid methacrylate hydrogels. The results showed
that uniaxial shear and compression, as well as biaxial sti-
mulation, induce the expression of chondrogenic marker
genes. Furthermore, showed that mechanostimulation of
tissue-engineered constructs consisting of clinically relevant
cells and biomaterials increases the biosynthesis and accu-
mulation of hyaline cartilage-specific ECM, producing
neotissues with higher native-like biochemical properties
[69]. Another study [70] investigated the effect of introdu-
cing gradients of interstitial flow on chondrocyte-seeded
agarose hydrogels using a bioreactor. They observed that
flow stimulation of chondrocyte-seeded agarose hydrogels
allows the enhance of glycosaminoglycans and type II
collagen deposition in the surface region of the hydrogel
exposed to flow. Furthermore, it was observed that inter-
stitial flow increases convective mass transport indepen-
dently of molecular size inside the boundary layer closer to
hydrogel surface and that the convective contribution to
transport decreases with depth in connection with interstitial
flow gradients [70]. A study made by Daly et al. [71]
investigated if dynamic bioreactor culture, at specific oxy-
gen conditions, could expedite the development of large
cartilage tissues using mesenchymal stem cell loaded algi-
nate hydrogels. The dynamic culture conditions were
investigated by performing the test at 20% O2 and 3% O2.
At 20% O2, dynamic culture substantially restrained chon-
drogenesis in engineered tissues of all sizes. However, at
3% O2 dynamic culture considerably increased the dis-
tribution and amount of cartilage matrix components, col-
lagen II and sulfated glycosaminoglycan and collagen II
when compared to static conditions. So, these results
showed that dynamic culture systems that offer suitable
nutrient disposal and a low oxygen environment can be
used to engineer large homogeneous cartilage tissues [71].
Bioreactors, despite allowing real-size models, using
multi-stimuli setups, have a lesser throughput than minia-
turized models, namely microphysiological systems that
decrease the volume of consumables, decrease sample size,
and increase monitoring capacity. Organ-on-a-chip tech-
nology has been more common in recent years and has been
applied to in vitro development of cartilage models in the
most recent years [72, 73]. These models show that this
technology already allows in vitro model production and
maintenance [72, 74], and explant culture [73].
Several studies show that microfluid-based chondrocyte
systems may present a new platform for future investigation
in the behavior of differentiated chondrocytes. A study
made by Rosser et al. [75] developed a 3D chondrocyte on-
a-chip model mimicking in vivo articular chondrocyte
morphology, cell distribution, metabolism, and gene
expression (Fig. 4ii). This model was established by loading
hydrogel-embedded primary (equine) chondrocytes and a
physiologic nutrient diffusion gradient across the simulated
matrix. The results showed that chondrocytes remained
viable with high Sox9, aggrecan, and Col2 expression
normal of articular chondrocytes. Furthermore, the chon-
drocytes were exposed to pro-inflammatory cytokines to
mimic the in vitro osteoarthritis model and the results
demonstrated that on-chip established equine cartilage react
to biochemical injury and respond to steroid treatment [75].
Another study [76] designed a microfluidic agarose-based
construct and established bioprocessing conditions to meet
nutrient transport requirements of a large, full-thickness
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articular cartilage construct. The results showed that
microfluidic agarose-based hydrogels approaching thicker
and more robust constructs allowed improve proliferation
and matrix deposition but not apparent mechanical proper-
ties suggesting that this platform has clinical utility [57]. A
study made by Li et al. [76] developed a facile, very low
cost-based microfluidic platform to produce visible light-
cured microgels composed of gelatin norbornene (GelNB)
and a poly(ethylene glycol) (PEG) cross-linker. The
microfluidic device was designed to encapsulate human
bone marrow-derived mesenchymal stem cells (hBMSCs)
and for be used articular cartilage tissue regeneration. The
results demonstrated that the process allows the rapid in situ
microencapsulation of hBMSCs under biocompatible
microfluidic-processing conditions. The hBMSCs presented
a remarkably high degree of chondrogenesis in the GelNB
microgels with chondro-inductive media, particularly
regarding the hyaline cartilage structure, with substantial
upregulation in type II collagen expression compared to the
bulk hydrogel and standard culture [76].
Besides the use of hydrogels as ECM in dynamic
in vitro models, the use of hydrogels as bioinks for bio-
printing of in vitro models has shown a great potential for
cartilage tissue engineering. The dynamic microenviron-
ment of ECM is not totally mimic from the traditional
static environment of the hydrogels and, 3D bioprinting
Fig. 4 (i) Mechanical stimulation bioreactor system. (a) Front view
depicting the bioreactor stand (anodized in blue) and the removable
polycarbonate culture chamber. (b) Close-up view of PTFE pistons
lowered into a standard 24-well plate on the actuator-driven sliding
platform. (c) Shear deformation of hydrogel construct fully immersed
in culture media. Reprinted with permission from [69]. (ii) (A) CAD
design of cartilage-on-a-chip device. (B) Photograph of an actual
cartilage-on-a-chip device showing loading of cell-laden hydrogel in
the top chamber. (C) Overview picture of three cell culture chambers
and right side showing one individual culture chamber featuring
CMFDA-stained primary equine chondrocytes cultivated on-chip. (D)
Intact cell-laden fibrin hydrogel clot released from the device before
downstream analyses and (E) histological section of chondrocytes-on-
a-chip. Reprinted from publication [75], Copyright (2021) with per-
mission from Elsevier
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allows adaptability, architecture control, and repeatability
that can overcome the limits of traditional biofabrication
systems [77]. The selection of biomaterials for the printing
mostly depends on their biocompatibility with cell growth
and function and also their printing characteristics,
extrudability, post-printing stability, such as viscosity
[78, 79]. After revising several systematic reviews the
most of the published works use a limited range of bioinks,
including gelatin, collagen, alginate, modified copolymer
PEG, hyaluronic acid, and photocurable acrylates/metha-
crylates to cartilage tissue engineering [78, 80]. The
development of these innovative bioinks gives to biome-
dical engineering community closer to expectations of
fabricated structures of ideal properties able of replicating
native tissues, while further improve regeneration and
therapeutic handicaps [77].
4 Conclusion and future perspectives
RA is a highly debilitating chronic autoimmune disease that
typically causes pain, swelling, and stiffness in the joints.
Although there are several treatments that allow an
improvement in the physical condition of patients, most of
them are not completely effective and have several serious
side effects. Several therapeutic approaches have been
developed over the past few years to improve efficacy and
decrease side effects caused by drugs. Hydrogels have a
unique combination of characteristics, high porosity, bio-
compatibility, biodegradation, and flexibility make them
useful in drug delivery applications. Through the literature
review where hydrogels were used to treat RA, it was
possible to verify that this drug delivery platform was able
to potentiate the effect of drugs when compared with tra-
ditional drugs, both in vitro and in vivo studies. Despite the
advances reached in the treatment of RA, it is important to
fill some gaps namely mimic the dynamic system existing in
the human body.
The drug development industry is facing a severe halt,
forcing a paradigm change. One of the most blatant reasons
for this hampering has been the use of animal experi-
mentation for drug testing. Experts from academia to the
industry recognize today that dynamic in vitro human
models are the alternative with better prospects since it
bypasses several of the problems of animal models.
The studies mentioned above allow demonstrated that
Gel-based systems as artificial extracellular matrices com-
bined with dynamic systems based in bioreactors and
microfluidic devices are promising preclinical models to
articular cartilage, with additional potential to be used in
several applications in regenerative medicine.
Considering the current models, diseased articular car-
tilage models will evolve in the following years for a
combination of intensive characterization of the bioma-
terials, cells, and fluid mechanics employed and biomi-
metic cellular diversity.
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